Aptevo Therapeutics (APVO) & BioCryst Pharmaceuticals (BCRX) Critical Review
Aptevo Therapeutics (NASDAQ: APVO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Valuation and Earnings
This table compares Aptevo Therapeutics and BioCryst Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aptevo Therapeutics||$36.43 million||2.63||-$112.41 million||($1.82)||-2.46|
|BioCryst Pharmaceuticals||$26.35 million||21.14||-$55.14 million||($0.64)||-8.84|
This is a summary of recent ratings and recommmendations for Aptevo Therapeutics and BioCryst Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aptevo Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 34.23%. BioCryst Pharmaceuticals has a consensus price target of $9.14, indicating a potential upside of 61.53%. Given BioCryst Pharmaceuticals’ higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Aptevo Therapeutics.
This table compares Aptevo Therapeutics and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
32.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 84.7% of BioCryst Pharmaceuticals shares are held by institutional investors. 15.6% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 5.6% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aptevo Therapeutics beats BioCryst Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Receive News & Stock Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related stocks with our FREE daily email newsletter.